Sign In
Buy ABBV
$217.07
+1.64 (+0.761%)
At Close: Jun 03, 2026
$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
10:36am, Friday, 30'th Jan 2026
/PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driven by over 50 FDA approvals in 2025, with 20 arriving in Q4 alone[1]. This
Stay Ahead of the Game With AbbVie (ABBV) Q4 Earnings: Wall Street's Insights on Key Metrics
10:20am, Friday, 30'th Jan 2026
Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for som
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
10:30pm, Thursday, 29'th Jan 2026
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability
10 Highest Rated Dividend Kings For Generations Of Income
10:10am, Thursday, 29'th Jan 2026
My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend
AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
08:00am, Thursday, 29'th Jan 2026
~3 out of 4 respondents said migraine attacks have stood in the way of romantic relationships, according to new Harris Poll survey Wife, mother, country music star, and entrepreneur Jessie James Decke
Why AbbVie Stock Trounced the Market in 2025
04:42pm, Wednesday, 28'th Jan 2026
The pharmaceutical sector mainstay has built an impressive and resilient portfolio. Fears of serious declines in the fundamentals following the loss of patent exclusivity for Humira were overblown.
Eaton Vance Worldwide Health Sciences Fund Reduces Stake in Novo Nordisk AS by 49.25%
03:01pm, Wednesday, 28'th Jan 2026
Exploring Strategic Moves in the Health Sciences Sector Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) recently submitted its N-PORT filing for
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Wednesday, 28'th Jan 2026
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie, SLB, Amphenol, And More On CNBC's 'Final Trades'
08:20am, Wednesday, 28'th Jan 2026
On CNBC's "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors recommended staying long on AbbVie.
- N ine e-posters presenting comprehensive Allergan Aesthetics portfolio data spanning first-in-class botulinum neurotoxin serotype E (TrenibotulinumtoxinE, "TrenibotE"), onabotulinumtoxinA, hyaluro
DSG Capital Advisors LLC Buys 22,700 Shares of AbbVie Inc. $ABBV
06:52am, Wednesday, 28'th Jan 2026
DSG Capital Advisors LLC lifted its stake in shares of AbbVie Inc. (NYSE: ABBV) by 129.6% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commiss
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
04:52pm, Tuesday, 27'th Jan 2026
The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical companies including Eli Lilly , Pfizer and AbbVie for the third cycle of the M
Is the Options Market Predicting a Spike in AbbVie Stock?
09:36am, Tuesday, 27'th Jan 2026
Investors need to pay close attention to ABBV stock based on the movements in the options market lately.
The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator
09:34am, Tuesday, 27'th Jan 2026
CHICAGO--(BUSINESS WIRE)--The AbbVie Foundation, a 501(c)(3) nonprofit working to drive transformative change and advance health equity in communities worldwide, in partnership with MATTER, the premie
Belpointe Asset Management LLC Increases Stake in AbbVie Inc. $ABBV
03:40am, Tuesday, 27'th Jan 2026
Belpointe Asset Management LLC increased its holdings in AbbVie Inc. (NYSE: ABBV) by 7.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange
